ThaiPR.NET https://www.thaipr.net/location/tel-aviv-israel-and-raleigh-nc Press Release Distribution Center of Thailand Fri, 24 Apr 2026 17:45:02 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[RedHill Accelerates Opaganib’s Nuclear Radiation Protection Program – Positive Data Published]]> https://www.thaipr.net/en/health_en/3268322 Thu, 17 Nov 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3268322 Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib’s potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy As an oral, small molecule pill that is highly stable with a more than five-year […]

The post RedHill Accelerates Opaganib’s Nuclear Radiation Protection Program – Positive Data Published appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma and South Korea’s Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill]]> https://www.thaipr.net/en/health_en/3119626 Tue, 09 Nov 2021 14:55:00 +0700 health_en https://www.thaipr.net/en/health_en/3119626 RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days’ volume weighted average price (VWAP) ending on the effective date RedHill granted Kukbo a right of first offer for opaganib, RHB-107 (upamostat) and Talicia® for South Korea […]

The post RedHill Biopharma and South Korea’s Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma’s Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant]]> https://www.thaipr.net/en/health_en/3092128 Mon, 30 Aug 2021 13:35:00 +0700 health_en https://www.thaipr.net/en/health_en/3092128 Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date    Opaganib’s unique, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is expected to maintain effect against other emerging variants The global 475-patient Phase 2/3 […]

The post RedHill Biopharma’s Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib]]> https://www.thaipr.net/en/health_en/3077778 Wed, 21 Jul 2021 08:15:00 +0700 health_en https://www.thaipr.net/en/health_en/3077778 Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus RedHill […]

The post RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19]]> https://www.thaipr.net/en/health_en/3067754 Tue, 22 Jun 2021 13:55:36 +0700 health_en https://www.thaipr.net/en/health_en/3067754 Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum Opaganib was associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated Opaganib’s global 475-patient Phase 2/3 study […]

The post RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 appeared first on ThaiPR.NET.

]]>